Surprisingly, in large cohort survival analysis of our study, DDX3 did not play a role in patient outcomes of lung cancer, hepatocellular carcinoma, and gliobalstoma which DDX3 has previously been reported to be an important tumor progression regulator [9, 10, 13, 16]. Here, DDX3X is linked to hepatocellular carcinoma.